Novo Nordisk A/S (NYSE:NVO)
| 91.30 Delayed Data As of Sep 22 |  +0.01 / +0.01%Today’s Change | 47.51 Today|||52-Week Range 100.88 | +34.92% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Year Trend | |||||
|---|---|---|---|---|---|---|
2015 | 2016 | 2017 | 2018 | |||
| Operating Activities | Net Income / Starting Line | 5.2B | 5.6B | 5.8B | 6.1B | |
| Depreciation | 437.7M | 454.7M | 435.2M | 602.9M | ||
| Total Other Cash Flow | 388.3M | 1.6B | 276.9M | 1.0B | ||
| Funds From Operations | 6.0B | 7.7B | 6.6B | 7.6B | ||
| Funds From/For Other Operating Expenses | 319.1M | 549.8M | 310.1M | 533.4M | ||
| Net Cash Flow - Operating Activities | 5.7B | 7.2B | 6.2B | 7.1B | ||
| Investing | Increase In Investments | -524.0M | -78.7M | 0.00 | -39.3M | |
| Decrease In Investments | 226.6M | 306.0M | 304.6M | 86.4M | ||
| Capital Expenditures | -772.8M | -1.0B | -1.2B | -1.5B | ||
| Fixed Asset Disposal | 342.9M | 1.0M | 1.4M | 2.1M | ||
| Other Investing - Uses | 0.00 | -16.6M | -6.1M | 0.00 | ||
| Other Investing - Sources | 0.00 | 3.4M | 11.1M | 0.00 | ||
| Net Cash Flow Investing | -902.1M | -1.0B | -1.0B | -1.9B | ||
| Financing | Short Term Borrowings | 0.00 | 0.00 | 0.00 | 14.9M | |
| Long Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Long Term Debt Reduction | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Net Proceeds Stock Sale | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Common Preferred Redeemed | -2.5B | -2.2B | -2.6B | -2.5B | ||
| Common Dividends | -1.9B | -3.5B | -2.9B | -3.0B | ||
| Cash Dividends Paid - Total | -1.9B | -3.5B | -2.9B | -3.0B | ||
| Other Sources - Financing | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Other Uses - Financing | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Net Cash Flow - Financing | -4.5B | -5.8B | -5.4B | -5.5B | ||
| Exchange Rate | Effect of Exchange Rate on Cash | 12.7M | -3.9M | -32.0M | 7.0M | |
| Net Change In Cash | 308.9M | 391.0M | -165.6M | -314.2M | ||